SKCPT is under clinical development by SK Chemicals and currently in Phase III for Osteoarthritis. According to GlobalData, Phase III drugs for Osteoarthritis have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SKCPT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SKCPT overview

SKCPT is under development for the treatment of knee osteoarthritis.

SK Chemicals overview

SK Chemicals is a chemical-based company that manufactures green chemicals such as polyesters, biomaterials, and high-performance resins. It provides chemical and pharmaceutical products and pharmaceutical drugs to treat erectile dysfunction, arthritis, peptic ulcer, gastroesophageal reflux disease (GERD), cancer and to improve blood circulation. The company offers an erectile dysfunction treatment, Mvix, and film-type erectile dysfunction treatment, MvixS. SK Chemicals serves different sectors including, automotive, chemicals, building and construction, energy, packaging, industrial manufacturing, sports, and consumer goods sectors. The company has operations in the US, Germany, China, Japan, and Singapore. SK Chemicals is headquartered in Seongnam, Gyeonggi-do, Seoul, South Korea.

For a complete picture of SKCPT’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.